With the theme “Harnessing Internal Strength to Jointly Prevent Cardiovascular and Comorbid Diseases”, the 2023 Expanded Imperial Capital Cardiovascular Science Conference was held on April 14–15 in the poetic city of Hue. The event was co-organized by the Vietnam National Heart Association and the Thua Thien Hue Cardiovascular Association.
The Organizing Committee presented flowers to sponsors, including STADA Pymepharco.
This year’s conference gathered nearly 500 participants, including professors, doctors, pharmacists, and cardiovascular experts from hospitals, universities, research institutes, and other invited organizations nationwide. The conference served as a forum for professionals and healthcare providers specializing in cardiovascular and comorbid conditions to explore the latest scientific research from both domestic and international experts in the field.
The conference featured 07 main topics, including: general cardiology, hypertension, endocrinology and cardiorenal diseases, cardiovascular imaging, coronary artery disease, arrhythmias and pacemakers, and cardiovascular risks, cardiac surgery, and heart failure. In addition, several Continuing Medical Education (CME) sessions were held on subjects such as hypertensive emergencies, pulmonary hypertension crises and the role of diagnostic imaging tools, dual antiplatelet therapy post-myocardial reperfusion, emergency cardiac ultrasound, early diagnosis and post-cardiac arrest care, ECG in cardiac emergencies, and emergency arrhythmia management.
These topics were presented by leading professors and experts from institutions such as the Vietnam National Heart Association, Cardiovascular Center of Hue Central Hospital, Hue University of Medicine and Pharmacy, Military Hospital 103, and the Vietnam Association of Diabetes and Endocrinology. The sessions provided crucial and practical insights to enhance treatment outcomes and save lives.
Delegates visited STADA Pymepharco’s exhibition booth.
STADA Pymepharco was honored to accompany this important scientific conference, showcasing its two EU-GMP-certified pharmaceutical manufacturing plants and a portfolio of high-quality, bioequivalent (BA-BE) products. These include specialized treatments for cardiovascular conditions, hypertension, diabetes, thrombosis, and hyperlipidemia.
With therapeutic efficacy equivalent to original brand-name drugs, high safety profiles, and more affordable pricing for Vietnamese patients (at only 30–50% of the cost of brand-name equivalents), STADA Pymepharco’s products offer healthcare professionals meaningful options to support patient care moving forward.
STADA Pymepharco – German Quality, Committed to Vietnamese Health!
Source: Sai Gon Giai Phong Newspaper
